mRNA Vaccines Market Size & Share 2026-2035

mRNA Vaccines Market Size

The mRNA vaccines market was valued at USD 6.2 billion in 2025. The market is expected to grow from USD 5.6 billion in 2026 to USD 7.2 billion in 2035, at a CAGR of 2.8% during the forecast period according to the latest report published by Global Market Insights Inc.^[1]

Diversification has begun, but from a narrow base. Moderna's mRESVIA became the first FDA-approved mRNA vaccine for respiratory syncytial virus prevention in May 2024, and its U.S. indication was expanded in June 2025 to adults aged 18 through 59 at increased risk of RSV-associated lower respiratory tract disease. Japan also authorized KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine, demonstrating that next-generation RNA architectures can enter commercial use outside the conventional nucleoside-modified mRNA model.

North America represented 45.3% of global revenue in 2025. U.S. revenue declined from USD 23.9 billion in 2022 to USD 2.6 billion in 2025, while Europe generated USD 2.0 billion in 2025. Asia Pacific is projected to record the highest regional CAGR, at 3.5%, through 2035. ^[2]

The next phase depends on whether indications with different purchasing and clinical-use patterns can produce durable revenue. RSV is projected to grow at an 8.4% CAGR, and mRESVIA's expanded U.S. label creates a broader adult risk-based population than its original older-adult authorization. Commercial success will depend less on the speed of RNA sequence design than on reimbursement, formulary access, seasonal contracting, and differentiation against established RSV vaccine alternatives.

The mRNA vaccines market is assessed globally for 2026-2035, with 2025 as the base year. Coverage includes product, application, patient age group, and end-use segments across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The competitive assessment covers Pfizer, BioNTech, and Moderna, with relevant pipeline developers discussed in context. ^[2]

Key Drivers

Rapid platform response and strain adaptation

mRNA development retains a practical speed advantage when antigen sequences change frequently. Vaccine developers can alter the encoded sequence while retaining much of the established LNP delivery, analytical, and manufacturing framework. Pfizer and BioNTech's FDA approval for an LP.8.1-adapted Comirnaty formulation in August 2025 demonstrated that strain adaptation remains commercially viable within a seasonal vaccination model. This capability has greatest value where epidemiological change, rather than long-duration product differentiation, drives demand. ^[3]

Commercial infrastructure built during COVID-19

Pandemic deployment established specialized RNA synthesis, LNP formulation, fill-finish, pharmacovigilance, and temperature-controlled distribution capabilities at global scale. Those assets lower the incremental operational burden of moving into adjacent respiratory indications, although they do not eliminate the need for indication-specific efficacy evidence, clinical contracting, and reimbursement decisions. ^[4] Pfizer's continued Comirnaty revenue and Moderna's multi-product respiratory portfolio show that the existing commercial base can fund diversification during a period of lower COVID-19 demand.

Government preparedness and technology-transfer activity

Public-sector support remains a source of platform demand, particularly where governments view domestic vaccine capacity as a health-security objective. In January 2025, HHS announced USD 590 million for Moderna's mRNA-based pandemic influenza vaccine development program. The WHO mRNA Technology Transfer Programme has also supported capability development among partner manufacturers in low- and middle-income countries, which could broaden future regional supply options.

LNP delivery innovation

LNP performance affects dose requirements, tolerability, tissue distribution, stability, and manufacturability. Advances in ionizable lipids and formulation design may improve delivery efficiency, while novel excipients create more demanding chemistry, manufacturing, and controls packages. Regulators increasingly expect detailed characterization of novel lipid components, meaning that delivery innovation can improve product performance but may also extend development and comparability work.

Expansion beyond COVID-19

RSV prevention provides the clearest near-term commercial test of mRNA diversification. mRESVIA received FDA approval for adults aged 60 years and older in 2024, then gained an expanded high-risk adult indication in 2025. Oncology programs may offer a second, longer-cycle opportunity: Moderna and Merck are advancing intismeran autogene in late-stage melanoma development, although trial progress should not be equated with commercial authorization.

Key Restraints

Manufacturing and distribution economics

mRNA vaccine production requires specialized inputs, including plasmid DNA templates, modified nucleotides, enzymes, capping reagents, and lipid components. The combination of input qualification, aseptic manufacturing, LNP processing, and cold-chain distribution can make entry expensive and can limit competitiveness in tender markets that prioritize delivered dose cost. A Médecins Sans Frontières process-cost model estimated that establishing capacity for 100 million annual mRNA vaccine doses required USD 127.1 million to USD 270 million in start-up investment.

Distribution conditions remain particularly important in lower-resource health systems. Cold-chain equipment, dependable electricity, and transportation capacity influence whether centrally manufactured vaccines can reach dispersed immunization sites without excessive waste or delivery cost. Evidence from the Democratic Republic of the Congo identified material cold-chain constraints across surveyed facilities, illustrating why manufacturing access alone does not ensure routine deployment.

A limited approved-product base

Commercial revenue is concentrated in COVID-19 vaccines, with RSV as the principal new approved application. mRESVIA generated USD 25 million in 2024, its first partial commercial year, compared with a global market of USD 8.5 billion. This contrast shows that non-COVID products have not yet reached a scale sufficient to offset falling COVID-19 sales. Pipeline activity in influenza, oncology, and other infectious diseases provides option value, but approvals, payer coverage, and real-world uptake remain necessary before pipeline assets can alter market structure.

Regulatory and quality complexity

mRNA products require extensive evidence on sequence integrity, impurities, potency, LNP attributes, stability, and manufacturing comparability. Novel lipid excipients can require data packages approaching the level expected for active pharmaceutical ingredients, particularly where the excipient materially affects biodistribution or safety. This regulatory burden favors developers with established CMC systems and creates a meaningful barrier for platform entrants seeking to alter delivery technologies while maintaining rapid development timelines. ^[5]

Lower COVID-19 vaccination uptake

COVID-19 demand has moved from emergency population vaccination to targeted seasonal use. During the 2024-2025 season, median vaccination coverage among adults aged 60 years and older was 8.7% across reporting EU/EEA countries. In the United States, COVID-19 vaccination coverage among children remained low, weakening the pediatric revenue base. In August 2025, HHS announced that it would wind down 22 BARDA mRNA vaccine development investments valued at nearly USD 500 million, adding uncertainty to the U.S. public funding environment.

RSV provides a plausible counterweight, but its projected 8.4% CAGR will not automatically translate into broad mRNA platform expansion. mRESVIA must compete for reimbursement, formulary placement, and provider adoption in a market already served by protein-based vaccines. The U.S. withdrawal of BARDA support from multiple mRNA projects further raises the value of diversified geographic funding, established manufacturing capacity, and commercially credible late-stage programs.

mRNA Vaccines Market Segment Analysis

By Product

Comirnaty remains the dominant product, holding approximately 70% of global mRNA vaccine revenue in 2025 and projected to reach USD 4.9 billion by 2035 at a 2.6% CAGR. Its position depends on annual strain updates, broad distribution reach, and continued use among populations at higher risk of severe COVID-19. ^[6] The 2025 LP.8.1 formulation approval demonstrates the operational importance of regulatory responsiveness within the seasonal vaccine cycle.

Spikevax generated USD 1.4 billion in 2025 and is projected to expand at a 3.1% CAGR through 2035. Its percentage growth outlook reflects a lower revenue base after the contraction of pandemic-era purchasing. Moderna's larger strategic distinction is its broader approved mRNA respiratory portfolio, which includes Spikevax, mRESVIA, and mNEXSPIKE.

mRESVIA is the principal non-COVID commercial growth asset. It is approved in the United States and Europe, with the U.S. label covering adults aged 18 through 59 at increased risk and older adults. Its growth potential is tied to RSV contracting and clinical-use patterns rather than to COVID-19 booster behavior.

Other products include mNEXSPIKE, Moderna's lower-dose COVID-19 vaccine approved by FDA in May 2025, and KOSTAIVE, the self-amplifying mRNA product authorized in Japan. KOSTAIVE is strategically significant because self-amplifying designs may achieve antigen expression at lower mRNA doses, although its commercial footprint remains geographically limited.

By Application

COVID-19 prevention accounted for 99.9% of 2025 market revenue. Its share is expected to decline as RSV and prospective pipeline applications grow, even if absolute COVID-19 revenue stabilizes among older adults and risk-based populations. Regulatory recommendations and annual strain selection will continue to shape seasonal procurement volumes.

RSV prevention is projected to achieve an 8.4% CAGR through 2035. The segment's growth case rests on mRESVIA's ability to secure access in a market where vaccination is often delivered through adult clinical care and competing RSV vaccines are already established. The indication therefore offers diversification, but not monopoly pricing or automatic channel adoption.

By Patient Age Group

The pediatric segment generated USD 2.0 billion in 2025 and is expected to grow at a 2.5% CAGR. Lower COVID-19 vaccination uptake among children and the absence of approved pediatric mRNA RSV products constrain diversification. Adult revenue is projected to expand at a 3.1% CAGR, supported by risk-based COVID-19 vaccination and the expanded mRESVIA indication for high-risk adults aged 18 through 59. The geriatric segment is projected to grow at a 2.7% CAGR, reflecting its established role in COVID-19 and RSV vaccination, alongside relatively mature penetration in higher-income markets.

By End Use

Government immunization programmes accounted for 63.2% of revenue in 2025 and are projected to generate USD 4.2 billion by 2035. This channel remains influential because national recommendations, tender structures, and stockpile policies directly affect order volumes. However, the change in U.S. BARDA policy illustrates that government support can shift from active development funding to narrower seasonal procurement. ^[7]

Hospitals and clinics are projected to be the fastest-growing end-use segment, at a 4.4% CAGR. This reflects the migration of vaccination from emergency mass campaigns toward provider-based seasonal administration, particularly for adult RSV prevention. Other end users, including academic institutions, NGOs, and vaccination centers, remain relevant mainly to clinical development, public-health delivery, and targeted access programs.

The most consequential imbalance remains the divergence between application growth and age-group demand. RSV prevention offers the fastest application growth at 8.4%, yet pediatric expansion remains constrained by low COVID-19 uptake and the lack of an approved pediatric mRNA RSV option. Products that extend the platform into adult RSV care may improve revenue resilience sooner than those aimed at broad population COVID-19 booster volumes.^[8]

mRNA Vaccines Market Regional Analysis

North America

North America held 45.3% of global market revenue in 2025. The United States remains the region's principal market, despite revenue falling from USD 23.9 billion in 2022 to USD 2.6 billion in 2025. The decline reflects the end of broad emergency purchasing, lower booster uptake, and the transition to seasonal commercial ordering. The August 2025 BARDA wind-down adds uncertainty for early-stage U.S.-funded mRNA development, even as commercial opportunities in COVID-19 and RSV remain.

Europe

Europe generated USD 2.0 billion in 2025. The EMA authorized mRESVIA for adults aged 18 years and older in August 2024, creating a broader eligible adult population than the product's original U.S. approval. However, low COVID-19 coverage among older adults across EU/EEA reporting countries indicates that demand recovery will depend on reimbursement decisions and distinct clinical demand for RSV vaccination rather than a return to mass booster campaigns.

Asia Pacific

Asia Pacific is projected to grow at a 3.5% CAGR, the highest regional rate through 2035. Japan provides a commercial proof point through KOSTAIVE's authorization and distribution, while regional growth also depends on expanding domestic manufacturing capability and regulatory pathways. Local clinical evidence requirements in large Asian markets can delay imported-product entry, but they may also support the development of domestic mRNA platforms and regional supply chains.

Latin America

Latin America is expected to record robust growth from a smaller base. Public immunization programmes, regional procurement mechanisms, and gradual improvements in cold-chain capacity will influence adoption more directly than private-market demand. The WHO mRNA Technology Transfer Programme may support longer-term localization of manufacturing capability, but local production must still be matched with financing, regulatory capacity, and viable procurement volumes.

Middle East & Africa

The Middle East and Africa are also expected to grow robustly from a low base. Gulf markets offer comparatively developed healthcare infrastructure, whereas many African markets face material cold-chain and last-mile distribution constraints. South Africa's role as the WHO mRNA technology-transfer hub is strategically important for capability building, but infrastructure reliability and sustainable procurement remain decisive for wider commercial deployment. ^[9]

Asia Pacific's projected 3.5% CAGR is supported by more than demand recovery. Japan's authorization of a self-amplifying mRNA vaccine demonstrates regional willingness to commercialize alternative RNA architectures, while domestic manufacturing and local regulatory pathways may reshape future supply access. In Latin America and Africa, the limiting factor is less likely to be antigen design than the ability to finance procurement, maintain temperature-controlled distribution, and convert technology-transfer capability into reliable routine vaccination supply.

mRNA Vaccines Market Share & Competitive Landscape

The authorized commercial market is concentrated among Pfizer, BioNTech, and Moderna. Moderna held approximately 70% market share in 2025, while Pfizer and BioNTech accounted for the remaining share. This structure reflects substantial barriers in LNP know-how, RNA manufacturing, regulatory documentation, commercial-scale quality systems, and government procurement relationships. ^[10]

Pfizer

Pfizer commercializes Comirnaty with BioNTech through a collaboration that includes equal gross-profit sharing in most markets outside China, Hong Kong, Macau, and Taiwan. Its 2025 Comirnaty revenue of USD 4.367 billion confirms the product's continued role in seasonal respiratory vaccination. The LP.8.1-adapted formulation approval reinforces Pfizer's ability to execute strain updates within the U.S. commercial market.

BioNTech

BioNTech contributes the mRNA technology foundation of the Comirnaty partnership while pursuing oncology diversification. Its pipeline includes autogene cevumeran and other oncology candidates, positioning the company to seek revenue streams beyond COVID-19 vaccination. These programs remain development-stage assets and should be distinguished from existing vaccine revenue.

Moderna

Moderna is the only company with three authorized mRNA respiratory products: Spikevax, mRESVIA, and mNEXSPIKE. Its strategy combines COVID-19 franchise management with RSV commercialization and late-stage oncology development. Moderna reported USD 3.2 billion in total 2024 revenue, including USD 3.1 billion from Spikevax and USD 25 million from mRESVIA in its initial partial year.

Pipeline participants

Arcturus Therapeutics and Meiji Seika Pharma are commercially relevant through KOSTAIVE in Japan. Daiichi Sankyo, Ethris, Sanofi, Providence Therapeutics, Strand Therapeutics, and Orna Therapeutics represent differentiated pipeline approaches spanning oncology, inhaled delivery, self-amplifying RNA, and circular RNA. These companies do not currently alter the concentrated authorized-market structure, but their platform choices could influence future dose economics, delivery routes, and product differentiation.

Recent Industry Developments

August 2025 - Pfizer and BioNTech receive FDA approval for LP.8.1-adapted Comirnaty

FDA approved the supplemental biologics license application for the LP.8.1-adapted Comirnaty formulation on August 27, 2025, for adults aged 65 years and older and individuals aged 5 through 64 years with at least one condition that increases the risk of severe COVID-19.

August 2025 - HHS winds down BARDA mRNA vaccine development investments

HHS announced the wind-down of 22 BARDA mRNA vaccine development investments, valued at nearly USD 500 million, on August 5, 2025. The action included contract terminations, de-scoping of mRNA work, and rejection of certain pre-award solicitations.

June 2025 - FDA expands mRESVIA eligibility

FDA expanded mRESVIA's indication on June 12, 2025 to include adults aged 18 through 59 years at increased risk of RSV-associated lower respiratory tract disease.

May 2025 - FDA approves mNEXSPIKE

FDA approved Moderna's mNEXSPIKE in May 2025 for adults aged 65 years and older and individuals aged 12 through 64 years with at least one underlying condition that places them at high risk for severe COVID-19.